JP2005046136A - 中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 - Google Patents
中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 Download PDFInfo
- Publication number
- JP2005046136A JP2005046136A JP2004181373A JP2004181373A JP2005046136A JP 2005046136 A JP2005046136 A JP 2005046136A JP 2004181373 A JP2004181373 A JP 2004181373A JP 2004181373 A JP2004181373 A JP 2004181373A JP 2005046136 A JP2005046136 A JP 2005046136A
- Authority
- JP
- Japan
- Prior art keywords
- collagenase
- neutral protease
- tissue
- protease
- islet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000035092 Neutral proteases Human genes 0.000 title claims abstract description 107
- 108091005507 Neutral proteases Proteins 0.000 title claims abstract description 107
- 108090000145 Bacillolysin Proteins 0.000 title claims abstract description 95
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 238000002803 maceration Methods 0.000 title abstract 3
- 108060005980 Collagenase Proteins 0.000 claims abstract description 87
- 102000029816 Collagenase Human genes 0.000 claims abstract description 87
- 229960002424 collagenase Drugs 0.000 claims abstract description 72
- 238000002955 isolation Methods 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract 2
- 238000003860 storage Methods 0.000 claims description 21
- 238000010494 dissociation reaction Methods 0.000 claims description 17
- 230000005593 dissociations Effects 0.000 claims description 17
- 241000193159 Hathewaya histolytica Species 0.000 claims description 10
- 102000035195 Peptidases Human genes 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 10
- 230000035899 viability Effects 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 210000000496 pancreas Anatomy 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 28
- 108090000790 Enzymes Proteins 0.000 description 28
- 229940088598 enzyme Drugs 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 28
- 239000000203 mixture Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 14
- 108010052014 Liberase Proteins 0.000 description 12
- 241000700159 Rattus Species 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 210000004923 pancreatic tissue Anatomy 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000005057 refrigeration Methods 0.000 description 5
- 238000007689 inspection Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- -1 tetrazolium compound Chemical class 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 101710105199 Collagenolytic protease Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000003366 colagenolytic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079919 digestives enzyme preparation Drugs 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 101000920185 Hathewaya histolytica Collagenase ColG Proteins 0.000 description 2
- 101000920186 Hathewaya histolytica Collagenase ColH Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010072787 Pancreatic steatosis Diseases 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10331171A DE10331171A1 (de) | 2003-07-09 | 2003-07-09 | Neutrale Protease (NP) und Produkt unter Verwendung von neutraler Protease für Gewebedissoziation sowie Verfahren zu dessen Herstellung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010005801A Division JP2010081941A (ja) | 2003-07-09 | 2010-01-14 | 中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005046136A true JP2005046136A (ja) | 2005-02-24 |
| JP2005046136A5 JP2005046136A5 (https=) | 2005-09-08 |
Family
ID=33441697
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004181373A Pending JP2005046136A (ja) | 2003-07-09 | 2004-06-18 | 中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 |
| JP2010005801A Pending JP2010081941A (ja) | 2003-07-09 | 2010-01-14 | 中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 |
| JP2011102735A Withdrawn JP2011147458A (ja) | 2003-07-09 | 2011-05-02 | 中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010005801A Pending JP2010081941A (ja) | 2003-07-09 | 2010-01-14 | 中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 |
| JP2011102735A Withdrawn JP2011147458A (ja) | 2003-07-09 | 2011-05-02 | 中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8440445B2 (https=) |
| EP (1) | EP1496112B1 (https=) |
| JP (3) | JP2005046136A (https=) |
| CN (1) | CN1626653A (https=) |
| AT (1) | ATE471979T1 (https=) |
| BR (1) | BRPI0402615B1 (https=) |
| CA (1) | CA2469137C (https=) |
| DE (2) | DE10331171A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010105820A1 (en) * | 2009-03-19 | 2010-09-23 | Roche Diagnostics Gmbh | Improved blends containing proteases |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07313159A (ja) * | 1994-03-16 | 1995-12-05 | Boehringer Mannheim Gmbh | クロストリジウム ヒストリチカムからの組換えタイプｉｉコラゲナーゼ及び細胞及び細胞群の単離のためへのその使用 |
| JPH09508026A (ja) * | 1994-06-24 | 1997-08-19 | ベーリンガー マンハイム コーポレーション | ヒストリチクス菌から得られるコラゲナーゼおよび２つの他のプロテアーゼの精製混合物 |
| JPH10500581A (ja) * | 1994-12-22 | 1998-01-20 | ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | クロストリジウム・ヒストリティカムからの組換えプロティナーゼ並びに細胞及び細胞群の単離のためのその使用 |
| JP2001510331A (ja) * | 1996-11-19 | 2001-07-31 | ロシュ ダイアグノスティックス ゲーエムベーハー | クロストリジウム・ヒストリチカム由来の組換えコラゲナーゼタイプ▲ｉ▼および細胞と細胞群の単離へのその使用 |
| WO2003004628A2 (de) * | 2001-07-02 | 2003-01-16 | Nordmark Arzneinmittel Gmbh & Co. Kg | Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989888A (en) | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
| US5830741A (en) * | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
-
2003
- 2003-07-09 DE DE10331171A patent/DE10331171A1/de not_active Withdrawn
-
2004
- 2004-05-25 EP EP04012321A patent/EP1496112B1/de not_active Expired - Lifetime
- 2004-05-25 AT AT04012321T patent/ATE471979T1/de active
- 2004-05-25 DE DE502004011298T patent/DE502004011298D1/de not_active Expired - Lifetime
- 2004-06-16 US US10/869,313 patent/US8440445B2/en not_active Expired - Fee Related
- 2004-06-17 CN CNA2004101005333A patent/CN1626653A/zh active Pending
- 2004-06-18 JP JP2004181373A patent/JP2005046136A/ja active Pending
- 2004-06-22 CA CA2469137A patent/CA2469137C/en not_active Expired - Fee Related
- 2004-07-08 BR BRPI0402615-2A patent/BRPI0402615B1/pt not_active IP Right Cessation
-
2010
- 2010-01-14 JP JP2010005801A patent/JP2010081941A/ja active Pending
-
2011
- 2011-05-02 JP JP2011102735A patent/JP2011147458A/ja not_active Withdrawn
-
2013
- 2013-04-15 US US13/862,773 patent/US8765471B2/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07313159A (ja) * | 1994-03-16 | 1995-12-05 | Boehringer Mannheim Gmbh | クロストリジウム ヒストリチカムからの組換えタイプｉｉコラゲナーゼ及び細胞及び細胞群の単離のためへのその使用 |
| JPH09508026A (ja) * | 1994-06-24 | 1997-08-19 | ベーリンガー マンハイム コーポレーション | ヒストリチクス菌から得られるコラゲナーゼおよび２つの他のプロテアーゼの精製混合物 |
| JPH10500581A (ja) * | 1994-12-22 | 1998-01-20 | ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | クロストリジウム・ヒストリティカムからの組換えプロティナーゼ並びに細胞及び細胞群の単離のためのその使用 |
| JP2001510331A (ja) * | 1996-11-19 | 2001-07-31 | ロシュ ダイアグノスティックス ゲーエムベーハー | クロストリジウム・ヒストリチカム由来の組換えコラゲナーゼタイプ▲ｉ▼および細胞と細胞群の単離へのその使用 |
| WO2003004628A2 (de) * | 2001-07-02 | 2003-01-16 | Nordmark Arzneinmittel Gmbh & Co. Kg | Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050142632A1 (en) | 2005-06-30 |
| ATE471979T1 (de) | 2010-07-15 |
| EP1496112A3 (de) | 2005-10-12 |
| DE10331171A1 (de) | 2005-01-27 |
| US8765471B2 (en) | 2014-07-01 |
| EP1496112A2 (de) | 2005-01-12 |
| BRPI0402615A (pt) | 2005-06-28 |
| CA2469137C (en) | 2015-11-24 |
| CA2469137A1 (en) | 2005-01-09 |
| US20130230922A1 (en) | 2013-09-05 |
| BRPI0402615B1 (pt) | 2017-07-04 |
| JP2010081941A (ja) | 2010-04-15 |
| US8440445B2 (en) | 2013-05-14 |
| JP2011147458A (ja) | 2011-08-04 |
| CN1626653A (zh) | 2005-06-15 |
| DE502004011298D1 (de) | 2010-08-05 |
| EP1496112B1 (de) | 2010-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wolters et al. | Different roles of class I and class II Clostridium histolyticum collagenase in rat pancreatic islet isolation | |
| Maestro et al. | Ovarian receptors for insulin and insulin-like growth factor I (IGF-I) and effects of IGF-I on steroid production by isolated follicular layers of the preovulatory coho salmon ovarian follicle | |
| Yoshizato | Biochemistry and cell biology of amphibian metamorphosis with a special emphasis on the mechanism of removal of larval organs | |
| Conlon et al. | Multiple bradykinin-related peptides from the skin of the frog, Rana temporaria | |
| JP2008528038A (ja) | 胚性幹細胞の指示された分化及びその利用 | |
| Fujisawa | Hydra regeneration and epitheliopeptides | |
| US5861278A (en) | HNF3δ compositions | |
| Kim et al. | Vitellogenin synthesis via androgens in primary cultures of tilapia hepatocytes | |
| Osada et al. | Puromycin-sensitive aminopeptidase is essential for the maternal recognition of pregnancy in mice | |
| Wang et al. | Cloning of zebrafish ovarian carbonyl reductase-like 20β-hydroxysteroid dehydrogenase and characterization of its spatial and temporal expression | |
| US6146626A (en) | Defined enzyme mixtures for obtaining cells and treating wounds | |
| Xing et al. | Polygenic expression of somatostatin in orange-spotted grouper (Epinephelus coioides): molecular cloning and distribution of the mRNAs encoding three somatostatin precursors | |
| Klöck et al. | Fractions from commercial collagenase preparations: use in enzymic isolation of the islets of Langerhans from porcine pancreas | |
| JP2011147458A (ja) | 中性プロテアーゼおよび中性プロテアーゼを使った組織解離用生成物ならびにその製造方法 | |
| Villaplana et al. | Identification of mammosomatotropes, growth hormone cells and prolactin cells in the pituitary gland of the gilthead sea bream (Sparus aurata L., Teleostei) using light immunocytochemical methods: an ontogenetic study | |
| BRAND et al. | Collagenase and the isolation of cells from bone | |
| KR20210024557A (ko) | 인슐린 생산용 소도 세포를 확산시키기 위한 조성물 및 방법 및 이의 치료적 용도 | |
| Salers | Evidence for the presence of prolyl oligopeptidase and its endogenous inhibitor in neonatal rat pancreatic β-cells | |
| Rungruangsak-Torrissen | Trypsin and its implementations for growth, maturation, and dietary quality assessment | |
| Conlon et al. | Kallikrein generates angiotensin II but not bradykinin in the plasma of the urodele, Amphiuma tridactylum | |
| KR20140077938A (ko) | 샘 세포의 생체 외 성숙 | |
| Toullec et al. | Molecular cloning and cellular expression of crustacean PC2-like prohormone convertase | |
| Madureira | Adult pancreatic tissue fate after pancreatic fragment autotransplantation into the spleen of the pancreatectomized dog | |
| Rungruangsak-Torrissen | Atlantic Salmon, Salmo salar L.: Genetic variations in protein metabolism and growth | |
| Christiansen | Mapping the proteolytic landscape in LEKTI deficiency human skin equivalent to model Netherton syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050520 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050520 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081111 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090107 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090915 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100212 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100218 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100416 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100527 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120131 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120229 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120305 |